Fremanezumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | CALCA, CALCB |
| Legal status | |
| Legal status |
|
| Identifiers | |
| ChemSpider |
|
Fremanezumab (INN) is a humanized monoclonal antibody directed against calcitonin-related polypeptides alpha and beta.[1] It is being developed for the prevention of migraine by Teva. It is in Phase III clinical trials as of July 2017.[2]
See also
- Other anti-migraine antibodies blocking the CGRP pathway
References
- ↑ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. WHO. 31 (1). 2017.
- ↑ H. Spreitzer (3 July 2017). "Neue Wirkstoffe: Galcanezumab, Fremanezumab und Eptinezumab". Österreichische Apothekerzeitung (in German) (14/2017).
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.